Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
- Conditions
- Neoplasms
- Registration Number
- NCT00725387
- Lead Sponsor
- Stanford University
- Brief Summary
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 214
- Patients older than 18-year-old, diagnosed with cancer
- Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them
- Patients who cannot complete a PET/CT scan
- Pregnant women
- Healthy volunteers
- Patients participating in other research studies
The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT. not defined
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Apollo Hospital
🇮🇳Chennai, India
Aalborg Hospital
🇩🇰Aalborg, Denmark
Pretoria Academic Hospital
🇿🇦Pretoria, South Africa
Stanford University School of Medicine
🇺🇸Stanford, California, United States
Coimbra University Hospital
🇵🇹Coimbra, Portugal